RGN and metabolic dysfunction-associated steatotic liver disease: Although further studies will be required to define the exact molecular mechanism of the altered lipid homeostasis and liver damage caused by decreases in SMP30 levels, our data strongly suggest that SMP30 is closely associated with NAFLD pathogenesis and might be a possible therapeutic target for NAFLD.